Field Trip Health Ltd. to Participate in Upcoming Investor Conferences
18 avr. 2022 09h00 HE
|
Field Trip Health, Ltd.
TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies,...
Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule FT-104
05 avr. 2022 07h51 HE
|
Field Trip Health, Ltd.
TORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced...
Field Trip Health Ltd. to Participate in Maxim Group 2nd Annual Virtual Growth Conference
23 mars 2022 08h00 HE
|
Field Trip Health, Ltd.
TORONTO, March 23, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies,...
Field Trip Health Ltd. to Participate in 34th Annual Roth Conference in March 2022
09 mars 2022 08h00 HE
|
Field Trip Health, Ltd.
TORONTO, March 09, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies,...
Field Trip Health Ltd. Reports Third Fiscal Quarter 2022 Financial Results and Provides Business Update
15 févr. 2022 17h15 HE
|
Field Trip Health, Ltd.
Earned patient services revenues of $1,360,811, an increase of 50% over the prior quarter and 330% year over year.At December 31, 2021, Field Trip had approximately $74.5 million in unrestricted cash...
Field Trip Health Ltd. Schedules Third Fiscal Quarter 2022 Financial Results Conference Call for February 16, 2022 at 8:30 AM ET
01 févr. 2022 08h00 HE
|
Field Trip Health, Ltd.
TORONTO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies,...
Field Trip Health Ltd. to Participate in Citi’s Psychedelic Drug Video Call Series
18 janv. 2022 08h00 HE
|
Field Trip Health, Ltd.
TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies,...
Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development
11 janv. 2022 10h00 HE
|
Field Trip Health, Ltd.
TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced...
Field Trip Announces Intention to Make Applications on Behalf of Patients to Health Canada’s Special Access Program (SAP) for Access to Psilocybin and MDMA-Assisted Therapies
06 janv. 2022 08h00 HE
|
Field Trip Health, Ltd.
TORONTO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced...
Field Trip Health Ltd. to Participate in H.C. Wainwright Bioconnect Virtual Conference in January 2022
05 janv. 2022 07h30 HE
|
Field Trip Health, Ltd.
TORONTO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies,...